Novo Energies Corporation Announces Dr. Michael Har-Noy’s Seminar to The Johns Hopkins Institute for Cell Engineering

NEW YORK, NY--(Marketwire -02/21/12)- Novo Energies Corporation ("Novo") (OTC.BB: NVNC.OB - News) today announced that Dr. Michael Har-Noy, Founder and Chief Executive Officer of Immunovative Therapies, Ltd. ("Immunovative"), was invited to present Immunovative's technologies to The Johns Hopkins Institute for Cell Engineering on February 14, 2012.

Immunovative is developing a new class of immunotherapy drugs designed to harness the power of the immune system to treat cancer and has 10 U.S. patents granted, 15 U.S. patents pending, 26 corresponding applications pending internationally and two experimental product candidates for the treatment of cancer in clinical development: AlloStim™ and AlloVax™.

The Johns Hopkins Institute for Cell Engineering represents the stem cell and immunotherapy research effort at The Johns Hopkins University School of Medicine, where faculty, fellows, postdocs and students and staff study some of the most exciting problems in stem cell science and immunotherapy today.

On December 15, 2011, Novo signed an exclusive License Agreement with Immunovative, pursuant to which Novo has been granted an exclusive, worldwide license to commercialize any products covered under Immunovative's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products including AlloStim™ and AlloVax™. Novo intends to change its name and symbol to better reflect its new direction.

About Immunovative Therapies, Ltd.:

Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. Immunovative specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit Immunovative's website at: http://www.immunovative.co.il

About Novo Energies Corporation:

Novo Energies Corporation is in the process of transforming into the cancer therapy area and intends to institute a name and symbol change to better reflect the new direction of the Company.

DISCLAIMER

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on Novo's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which Novo has little or no control. Such forward-looking statements are made only as of the date of this release, and Novo assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in Novo's Form 10-K for its fiscal year ended March 31, 2011, and other documents filed from time to time by Novo with the Securities and Exchange Commission.

View post:
Novo Energies Corporation Announces Dr. Michael Har-Noy's Seminar to The Johns Hopkins Institute for Cell Engineering